BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
PRKCA
,
nitric oxide metabolic process
,
Ischemia
,
Heart
,
Laryngoscope
,
Lovastatin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
PAC 1
Summary
General Info
Curated Studies
Most Correlated Studies
Garvan Immune Atlas Human: Analysis of stimulated cells vs. non-stimulated cells
Explore Curated Studies Results
Literature
Most Relevant Literature
DUSP2-mediated inhibition of tubular epithelial cell pyroptosis confers nephroprotection in acute ki…
DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment…
Interfering with Dusp2 alleviates high glucose-induced vascular endothelial cell dysfunction by prom…
Calcium flux control by Pacs1-Wdr37 promotes lymphocyte quiescence and lymphoproliferative diseases.
Apatinib combined with Keytruda treatment induces apoptosis of gastric carcinoma cells through CES4/…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol
PACS System in the Training of Ophthalmologists
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ